Fate Therapeutics Inc. (FATE)
FATE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.00
-6.10% on the day
Market cap
$239.6M
Micro cap
Revenue · 2025
$6.6M
-51.2% on 2024
Net income · 2025
-$136.3M
-2051.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | FATE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001434316 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.6M |
| Net income | -$136.3M |
| Operating income | -$147.7M |
| Net margin | -2051.1% |
| Operating margin | -2222.4% |
| Revenue growth | -51.2% |
| Cash | $46.6M |
| Total assets | $318.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 36.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-05-02 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-28 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 848 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SABS | SAB Biotherapeutics Inc. | $2.68 | -5.30% | $243.8M |
| IKT | Inhibikase Therapeutics Inc. | $1.76 | -4.61% | $245.6M |
| IPSC | Century Therapeutics Inc. | $1.38 | -4.17% | $249.9M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.9083 | -4.80% | $229.7M |
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
| LXEO | Lexeo Therapeutics Inc. | $2.74 | -9.87% | $224.8M |
| XFOR | X4 Pharmaceuticals Inc. | $2.60 | -7.80% | $257.8M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $2.75 | -1.08% | $221.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier